GfK's Deanna Hertz, Senior Consultant, Market Access, will be presenting "The Impact of Health Economic Evidence on the Coverage and Reimbursement of New Prenatal Diagnostics" at the 4th Annual Advances in Prenatal Diagnostics Conference.
The Impact of Health Economic Evidence on the Coverage and Reimbursement of New Prenatal Diagnostics
Tuesday, November 29 - 9:45AM
In order to maximize coverage and adoption for new diagnostic technologies in prenatal testing, payers are requiring companies to demonstrate the potential economic as well as clinical benefits of using the new technology. Budget impact and clinical effectiveness models, which are an effective way to capture and articulate the potential value of a new technology, will be discussed.